129 related articles for article (PubMed ID: 16061682)
1. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.
Dote H; Cerna D; Burgan WE; Camphausen K; Tofilon PJ
Cancer Res; 2005 Aug; 65(15):6967-75. PubMed ID: 16061682
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of hsp90 compromises the DNA damage response to radiation.
Dote H; Burgan WE; Camphausen K; Tofilon PJ
Cancer Res; 2006 Sep; 66(18):9211-20. PubMed ID: 16982765
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
4. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.
Russell JS; Burgan W; Oswald KA; Camphausen K; Tofilon PJ
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3749-55. PubMed ID: 14506167
[TBL] [Abstract][Full Text] [Related]
6. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation.
Machida H; Matsumoto Y; Shirai M; Kubota N
Int J Radiat Biol; 2003 Dec; 79(12):973-80. PubMed ID: 14713575
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Hsp90: a multitarget approach to radiosensitization.
Camphausen K; Tofilon PJ
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4326-30. PubMed ID: 17671112
[TBL] [Abstract][Full Text] [Related]
8. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
[TBL] [Abstract][Full Text] [Related]
9. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts.
Eiseman JL; Lan J; Lagattuta TF; Hamburger DR; Joseph E; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2005 Jan; 55(1):21-32. PubMed ID: 15338192
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin.
Kabakov AE; Makarova YM; Malyutina YV
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):858-65. PubMed ID: 18410996
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis.
Machida H; Nakajima S; Shikano N; Nishio J; Okada S; Asayama M; Shirai M; Kubota N
Cancer Sci; 2005 Dec; 96(12):911-7. PubMed ID: 16367912
[TBL] [Abstract][Full Text] [Related]
13. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
14. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
15. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
16. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
18. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549.
Sithanandam G; Fornwald LW; Fields J; Anderson LM
Oncogene; 2005 Mar; 24(11):1847-59. PubMed ID: 15688028
[TBL] [Abstract][Full Text] [Related]
20. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling.
Janmaat ML; Rodriguez JA; Jimeno J; Kruyt FA; Giaccone G
Mol Pharmacol; 2005 Aug; 68(2):502-10. PubMed ID: 15908515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
